BrainChild Bio develops chimeric antigen receptor T-cell therapies engineered to treat tumors of the central nervous system.
BrainChild Bio has raised $116.0M in total funding. The most recent round was Series A. The last funding was announced in September 2026.
BrainChild Bio's investors include WRF Capital, Seattle Children’s, ScaleReady.
BrainChild Bio is headquartered in Seattle, United States.
BrainChild Bio develops chimeric antigen receptor T-cell therapies engineered to treat tumors of the central nervous system.
BrainChild Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BrainChild Bio — Funding & Investors." VCBacked, September 8, 2026, https://www.vcbacked.co/company/brainchild-bio. Accessed October 17, 2026.
VCBacked. (2026). BrainChild Bio — Funding & Investors. Retrieved October 17, 2026, from https://www.vcbacked.co/company/brainchild-bio
{{cite web |title=BrainChild Bio — Funding & Investors |url=https://www.vcbacked.co/company/brainchild-bio |website=VCBacked |access-date=October 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated